STOCK TITAN

Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Larimar Therapeutics (LRMR) completed its application seeking accelerated FDA approval of nomlabofusp for adults and children with Friedreich’s ataxia.

The application uses frataxin, a protein, as a proposed surrogate endpoint—a measure intended to stand in for clinical benefit. FDA previously indicated willingness to consider it; approval remains subject to review. Patients are enrolling in the confirmatory Phase 3 FORWARD-FA study. Larimar targets application acceptance in early 2027, approval in mid-2027 and a U.S. launch in Q3 2027, if approved.

Third-quarter net loss narrowed to $31.1 million, or $0.29 per common share, from $47.7 million, or $0.61, a year earlier. Research spending fell, while administrative spending increased. Cash, cash equivalents and marketable securities totaled $128.7 million at September 30, 2026; the company projects funding into late Q2 2027.

Loading...
Loading translation...
13 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 7 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointNomlabofusp accelerated-approval application completed for adults and pediatric patients with Friedreich’s ataxia.
  • Moderate pointFDA indicated the existing data package appears capable of supporting application submission and review.
  • Moderate pointFDA reaffirmed willingness to consider frataxin as a novel surrogate endpoint.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Larimar targets early 2027 application acceptance and mid-2027 U.S. approval.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Larimar targets a Q3 2027 U.S. launch, if approved.
  • Moderate pointThird-quarter net loss narrowed to $31.1 million, or $0.29 per common share, versus $47.7 million, or $0.61.
  • Moderate pointThird-quarter research and development expenses fell to $25.9 million from $44.9 million a year earlier.
6 minor points
  • Minor pointConfirmatory Phase 3 FORWARD-FA is enrolling patients globally.
  • Minor pointOpen-label study additional participant enrollment continues.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Larimar plans an open-label study safety update in Q1 2027.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Larimar targets obtaining and monetizing a Rare Pediatric Disease Priority Review Voucher in mid-2027, if approved.
  • Minor pointNine-month net loss narrowed to $93.5 million, or $0.90 per common share, versus $103.2 million, or $1.50.
  • Minor pointNine-month research and development expenses fell to $79.0 million from $94.9 million a year earlier.

Negative

  • Major pointCommon shares outstanding increased to 104,634,619 at September 30, 2026, from 83,090,392 at December 31, 2025.
  • Moderate pointNomlabofusp approval remains subject to FDA review; the proposed surrogate endpoint has not been accepted.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Projected cash runway extends only into late Q2 2027, before the targeted Q3 2027 launch.
  • Moderate pointThird-quarter general and administrative expenses rose to $6.5 million from $4.6 million a year earlier.
  • Minor pointNine-month general and administrative expenses rose to $19.0 million from $13.6 million a year earlier.
2 minor points
  • Minor pointOther income fell to $1.329 million quarterly and $4.402 million year-to-date, versus $1.787 million and $5.304 million.
  • Minor pointPreferred shares outstanding increased to 500,000 at September 30, 2026, from 250,000 at December 31, 2025.

News Explained

At September 30, 2026, Larimar reported 104,634,619 common shares outstanding versus 83,090,392 at December 31, 2025, reducing the common-share ownership represented by unchanged holdings; authorized shares were 215 million versus 115 million, but authorization alone is not an issuance.

Key Figures

Cash and marketable securities: $128.7 million Projected cash runway: Into late Q2 2027 Third-quarter net loss: $31.1 million vs. $47.7 million +4 more
Cash and marketable securities
$128.7 million
As of September 30, 2026
Projected cash runway
Into late Q2 2027
Company projection
Third-quarter net loss
$31.1 million vs. $47.7 million
Q3 2026 vs. Q3 2025
Research and development expenses
$25.9 million vs. $44.9 million
Q3 2026 vs. Q3 2025
General and administrative expenses
$6.5 million vs. $4.6 million
Q3 2026 vs. Q3 2025
BLA submission acceptance
Early 2027
Potential upcoming milestone
U.S. approval
Mid-2027
Potential milestone; subject to FDA review

Previous Earnings Reports

2 past events · Latest: Aug 04
Same Type 2 events
  1. Aug 04

    Q2 earnings update

    24h Move
    +3.3%

    Initial BLA module submitted; FDA considered FXN a potential surrogate endpoint; confirmatory Phase 3 anticipated.

  2. May 14

    Q1 earnings update

    24h Move
    -5.1%

    Outlined rolling BLA plans and a global Phase 3 study; projected cash runway into Q2 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

accelerated approval, surrogate endpoint, exposure-response analysis, pharmacodynamic markers
4 terms
accelerated approval regulatory
"BLA submission seeking accelerated approval of nomlabofusp"
Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.
surrogate endpoint medical
"using FXN as a novel surrogate endpoint"
A surrogate endpoint is a measurable substitute used in a clinical trial—like a lab test or imaging result—that stands in for a direct patient benefit, such as longer life or improved daily function. Investors care because regulators may accept these quicker, earlier signals to clear or fast-track a treatment, which can shorten development time, reduce costs and change a drug’s market prospects; think of it as using a thermometer to predict recovery instead of waiting for full healing.
exposure-response analysis medical
"exposure-response analysis linking nomlabofusp exposure to clinical outcomes"
Exposure-response analysis studies how the amount of a drug or treatment in the body relates to its benefits and side effects, like tracking how turning a faucet changes water flow. Investors use it to judge whether a therapy works predictably, what dose is likely safe and effective, and how likely regulators and doctors will accept it; that influences development costs, approval chances, and commercial potential.
pharmacodynamic markers medical
"exploratory gene expression and lipid pharmacodynamic markers data"
Measurements that show a drug or therapeutic intervention is producing a biological effect in the body; these can be molecules, cells, enzyme activities, imaging signals or other lab values that change after dosing and track the drug’s mechanism of action or target engagement. Pharmacodynamic markers indicate that a treatment is doing something biologically expected (and can show dose–response or timing), but they are not by themselves proof of clinical benefit or long‑term safety and often serve as intermediate or surrogate signals used in early clinical trials and regulatory assessments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Completed BLA submission seeking accelerated approval of nomlabofusp for adults and pediatric patients with FA; potential to be the first disease-modifying therapy to address root cause of disease
  • Previously disclosed FDA alignment on key BLA elements, including willingness to consider skin frataxin as a potential novel surrogate endpoint
  • Patients currently enrolling in FORWARD-FA, the global confirmatory Phase 3 study for nomlabofusp
  • $128.7 million in cash, cash equivalents and marketable securities as of September 30, 2026, with projected cash runway into late Q2 2027

BALA CYNWYD, Pa., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter 2026 operating and financial results.

“Completing the BLA submission for nomlabofusp marks a major milestone for Larimar and the Friedreich’s ataxia (FA) community,” said Carole Ben-Maimon, M.D., Chief Executive Officer of Larimar. “The next 12 months are expected to bring several pivotal registrational catalysts, including FDA review of our application and progression of FORWARD-FA, our global confirmatory Phase 3 study. In parallel, we are preparing for a potential U.S. launch in the third quarter of 2027, if approved, while evaluating options to support global commercialization. We are energized by progress across our regulatory, clinical and commercial plans and focused on bringing nomlabofusp to adults and pediatric patients with FA as a therapy designed to address the underlying cause of the disease and potentially alter its course.”

Highlights

  • Submitted BLA. Larimar completed its rolling BLA submission seeking accelerated approval of nomlabofusp for the treatment of FA using FXN as a novel surrogate endpoint. Approval will be a matter of FDA review. The submission highlights include:
    • Data Package Supporting Submission and Review: FDA reviewed OL study data submitted in a briefing package and confirmed in minutes from the multidisciplinary Type B pre-BLA meeting that the existing data package appears capable of supporting submission and review of a BLA seeking accelerated approval of nomlabofusp as a treatment for patients with FA.
    • FXN as a Potential Surrogate Endpoint: In previously disclosed interactions, FDA reaffirmed its willingness to consider FXN as a novel surrogate endpoint and indicated that Larimar’s exposure-response analysis linking nomlabofusp exposure to clinical outcomes is the type of analysis that could support the BLA submission.
    • Additional Biological Evidence: FDA previously noted that prospectively collected exploratory gene expression and lipid pharmacodynamic markers data may help further characterize the biological activity of nomlabofusp beyond tissue FXN concentrations.
  • Three Poster Presentations at ICAR. In November, Larimar presented previously disclosed open label study findings and new lipid and gene expression analyses at the 2026 International Congress for Ataxia Research (ICAR).
  • Continued Advancement of OL Study. Enrollment of additional participants continues in the open label study.

Potential Upcoming Milestones

  • BLA Submission Acceptance: Early 2027
  • Open Label Study Safety Update: Q1 2027
  • U.S. Approval: Mid-2027
  • Obtaining & Monetizing the Rare Pediatric Disease Priority Review Voucher: Mid-2027, if approved
  • U.S. Launch: Targeting Q3 2027 launch, if approved.

Third Quarter 2026 Financial Results 

As of September 30, 2026, the Company had cash, cash equivalents and marketable securities totaling $128.7 million. The Company projects its cash runway into late Q2 2027.

Third quarter of 2026 compared to the third quarter of 2025

The Company reported a net loss for the third quarter of 2026 of $31.1 million, or $0.29 per common share, compared to a net loss of $47.7 million, or $0.61 per common share, for the third quarter of 2025.

Research and development expenses for the third quarter of 2026 were $25.9 million compared to $44.9 million for the third quarter of 2025. The decrease in research and development expenses was primarily driven by a $19.3 million decrease in drug manufacturing activities at our third-party manufacturers.

General and administrative expenses were $6.5 million in the third quarter of 2026 compared to $4.6 million in the third quarter of 2025. The increase in general and administrative expenses primarily related to the acceleration of commercial activities as we prepare for the third quarter 2027 launch of nomlabofusp, if approved. This included an increase of $0.6 million in professional fees related to commercial consulting services performed, an increase of $0.5 million in legal fees supporting commercialization and development efforts, an increase of $0.3 million of increased compensation costs associated with additional commercial and related headcount and an increase of $0.3 million of stock compensation costs related to grants issued in 2026.

Nine months ended September 30, 2026 compared to the nine months ended September 30, 2025

The Company reported a net loss for the first nine months of 2026 of $93.5 million, or $0.90 per common share, compared to a net loss of $103.2 million, or $1.50 per common share, for the first nine months of 2025.

Research and development expenses for the nine months ended September 30, 2026, were $79.0 million compared to $94.9 million for the nine months ended September 30, 2025. The decrease in research and development expenses was primarily driven by a $20.1 million decrease in drug manufacturing activities at our third-party manufacturers, partially offset by an increase of $4.1 million in professional, software and consulting fees associated with our ongoing and planned clinical trials, data analysis costs, FDA inspection readiness expenditures, as well as Biologics License Application preparation costs.

General and administrative expenses were $19.0 million for the first nine months of 2026 compared to $13.6 million for the nine months ended September 30, 2025. The increase in general and administrative expenses primarily related to the acceleration of commercial activities as we prepare for planned third quarter 2027 launch of nomlabofusp, if approved. This included an increase of $2.2 million in professional fees related to commercial consulting services performed, an increase of $1.3 million of increased compensation costs associated with additional commercial and related headcount, an increase of $1.0 million in legal fees supporting commercialization and development efforts and an increase of $0.5 million of stock compensation costs related to grants issued in 2026 primarily associated with increased headcount period over period.

About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Forward-Looking Statements
This press release contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar’s ability to develop and commercialize nomlabofusp and any other planned product candidates; the potential of nomlabofusp to address the underlying cause of FA and provide clinical benefit; the interpretation of clinical, biomarker and safety data and their ability to support the BLA; expectations regarding the FDA’s acceptance for filing, review and potential approval of the BLA, including consideration of skin FXN as a potential novel surrogate endpoint; Larimar’s planned research and development efforts, including the design, timing and conduct of FORWARD-FA; interactions with FDA; expectations regarding the potential for, accelerated approval or accelerated access and the impact of such accelerated access on the FDA’s review timeline Larimar’s preparations for and timing of a potential launch, if approved; the potential award and future sale of a Rare Pediatric Disease Priority Review Voucher; and Larimar’s overall development plans, business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar’s product development activities, nonclinical studies and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later non-clinical or clinical trials, and assessments; delays in patient recruitment, including as a result of changes in clinical protocols and adverse events; that the FDA may not ultimately agree with Larimar’s nomlabofusp development strategy or determine that skin FXN is not an acceptable surrogate endpoint for accelerated approval; that completion of the BLA submission does not assure acceptance for filing or accelerated approval and that FDA may require additional information or studies; Larimar’s ability to realize the benefits of Breakthrough Therapy Designation; the potential impact of public health crises on Larimar’s future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar’s ability and the ability of third-party manufacturers Larimar engages to optimize and scale nomlabofusp’s manufacturing process; Larimar’s ability to obtain regulatory approvals for nomlabofusp and future product candidates; Larimar’s ability to successfully develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar’s ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar’s management’s views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715


Larimar Therapeutics, Inc.
Consolidated Balance Sheets
(In thousands except share data)
(unaudited)
  September 30, December 31,
   2026   2025 
Assets    
Current assets:    
Cash and cash equivalents $76,986  $85,412 
Marketable securities  51,672   51,440 
Prepaid expenses and other current assets  7,496   5,170 
Total current assets  136,154   142,022 
Property and equipment, net  597   622 
Operating lease right-of-use assets  2,840   2,069 
Restricted cash  456   606 
Other assets  457   523 
Total assets $140,504  $145,842 
Liabilities and Stockholders’ Equity    
Current liabilities:    
Accounts payable $5,108  $5,216 
Accrued expenses  29,155   58,474 
Operating lease liabilities, current  1,382   1,105 
Total current liabilities  35,645   64,795 
Operating lease liabilities  3,393   2,962 
Total liabilities  39,038   67,757 
Commitments and contingencies (See Note 8)    
Stockholders’ equity:    
Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 500,000 and 250,000 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively  1   — 
Common stock, $0.001 par value per share; 215,000,000 and 115,000,000 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 104,634,619 and 83,090,392 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively  104   83 
Additional paid-in capital  629,741   512,779 
Accumulated deficit  (528,361)  (434,831)
Accumulated other comprehensive (loss) gain  (19)  54 
Total stockholders’ equity  101,466   78,085 
Total liabilities and stockholders’ equity $140,504  $145,842 


Larimar Therapeutics, Inc.
Consolidated Statements of Operations
(In thousands, except share and per share data)
(unaudited)
     
 Three Months Ended September 30,Nine Months Ended September 30,
  2026  2025  2026  2025 
Operating expenses:    
Research and development$25,925 $44,931 $78,956 $94,851 
General and administrative 6,539  4,568  18,976  13,628 
Total operating expenses 32,464  49,499  97,932  108,479 
Loss from operations (32,464) (49,499) (97,932) (108,479)
Other income, net 1,329  1,787  4,402  5,304 
Net loss$(31,135)$(47,712)$(93,530)$(103,175)
     
Comprehensive loss:    
Net loss$(31,135)$(47,712)$(93,530)$(103,175)
Other comprehensive loss:    
Unrealized loss on marketable securities (7) 75  (73) (82)
Total other comprehensive loss (7) 75  (73) (82)
Total comprehensive loss$(31,142)$(47,637)$(93,603)$(103,257)
     
Basic and diluted net loss per share:    
Common stock$(0.29)$(0.61)$(0.90)$(1.50)
Preferred stock (2.85)$—  (8.98) — 
Weighted-average shares used in computing basic and diluted net loss per share:    
Common stock 104,211,155  78,324,767  99,355,705  68,824,826 
Preferred stock 500,000  —  480,769  — 



FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Larimar expect FDA approval and launch of nomlabofusp?

Larimar targets mid-2027 U.S. approval and a Q3 2027 U.S. launch, if approved. Application acceptance is a potential milestone for early 2027; completing the submission does not constitute approval.

What were Larimar’s third-quarter 2026 losses and cash runway?

Larimar reported a $31.1 million net loss, or $0.29 per common share, and projects cash runway into late Q2 2027. Cash, cash equivalents and marketable securities totaled $128.7 million at September 30, 2026.

Why did Larimar’s research and development expenses fall in 2026?

Lower spending on drug manufacturing at third-party manufacturers primarily drove the decline: $19.3 million less in the third quarter and $20.1 million less over nine months. The nine-month reduction was partly offset by $4.1 million more in professional, software and consulting fees associated with clinical trials, data analysis, FDA inspection readiness and application preparation.

What additional biological evidence could support Larimar’s nomlabofusp application?

FDA previously indicated that exploratory gene expression and lipid pharmacodynamic marker data collected prospectively may help characterize nomlabofusp’s biological activity beyond tissue frataxin concentrations. FDA also indicated that Larimar’s analysis linking drug exposure to clinical outcomes is the type of analysis that could support the application.

Keep reading